Orphan Lung
Endocrine
Developing life more humann
We’re focused on creating the cutting-edge therapies and technologies that can change life for the better.
Our Technosphere® technology can be applied to a number of therapeutic areas that are both in high demand for innovation, and in need for a different kind of treatment option for people living with these conditions. Our pipeline reflects how we, as well as our partners, are applying MannKind technology to develop and advance new products to not only help people take control of their health, but truly thrive.
| product (collaboration and/or details) |
targeted indication(s) | pre-IND / formulation | phase 1 | phase 2 | phase 3 | marketed |
|---|---|---|---|---|---|---|
| Afrezza® (insulin human) Inhalation Powder - USA | T1 and T2 diabetes mellitus (adults) | |||||
|
Afrezza® (insulin human) Inhalation Powder - INT’L International Expansion: Brazil (Biomm) |
T1 and T2 diabetes mellitus (adults) | |||||
|
Afrezza® (insulin human) Inhalation Powder - INT’L International Expansion: India (Cipla) |
T1 and T2 diabetes mellitus (adults) | |||||
|
Pediatric Afrezza® (insulin human) Inhalation Powder Indication Expansion |
T1 and T2 diabetes mellitus (pediatrics) | |||||
| V-Go® (once-daily wearable insulin delivery device) | management of diabetes mellitus in persons requiring insulin (adults) | |||||
|
Tyvaso DPI® (collaboration with United Therapeutics) |
pulmonary arterial hypertension / pulmonary hypertension associated with interstitial lung disease | |||||
| MNKD-101 (clofazimine inhalation suspension) | nontuberculous mycobacterial lung disease | |||||
| MNKD-201 (nintedanib DPI) | idiopathic pulmonary fibrosis | |||||
| MNKD-301 (dornase alfa) | cystic fibrosis | |||||
|
MNKD-501 (TGF-β) (collaboration with Thirona Bio) |
idiopathic pulmonary fibrosis |
